Comparative Pharmacology
Head-to-head clinical analysis: ELIXOPHYLLIN versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXOPHYLLIN versus VOSPIRE ER.
ELIXOPHYLLIN vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits phosphodiesterase, increasing intracellular cAMP, leading to bronchodilation and anti-inflammatory effects.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/mL). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator